NIVEN RALPH

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
25
Insider Sells Sum
$1.84M

Insider Activity of NIVEN RALPH

According to the SEC Form 4 filings, NIVEN RALPH, being in a position of

  1. CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 9200 shares for $168,365,
    over all time since 2022-08-18, has bought 0 shares, and sold 79350 shares for $1.48M.

The largest sale of all time was on 2023-11-22 and amounted to 13800 shares of Aerovate Therapeutics, Inc. for $207,000.

Biography of NIVEN RALPH

No biography is available at this moment.

2024-02-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,600
0.0155%
$17.45$80,249-84.95%
2024-01-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,600
0.0161%
$19.16$88,116-10.62%
2023-12-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,600
0.0168%
$16.30$74,996+16.89%
2023-11-22SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
13,800
0.0491%
$15.00$207,000+23.09%
2023-07-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.0092%
$17.30$38,915+4%
2023-06-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.0093%
$16.26$36,576+7.66%
2023-05-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.0087%
$20.87$46,957-22.13%
2023-04-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.009%
$18.20$40,942-7.92%
2023-03-06SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,500
0.0183%
$23.75$106,879-28.28%
2023-02-06SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,500
0.0179%
$24.27$109,224-31.68%
2023-01-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,500
0.0181%
$26.40$118,809-36.43%
2022-12-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.0089%
$17.38$39,114-3.25%
2022-12-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,500
0.0178%
$17.38$78,228-3.25%
2022-11-07SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.0099%
$19.20$43,194+1.65%
2022-11-07SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,500
0.0198%
$19.20$86,389+1.65%
2022-10-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
2,250
0.0088%
$15.75$35,447
2022-10-05SaleAerovate Therapeutics, Inc.
AVTE
CHIEF SCIENTIFIC OFFICER
4,500
0.0176%
$15.75$70,893
2022-09-06SaleAerovate Therapeutics, Inc.
AVTE
Chief Scientific Officer
4,500
0.0196%
$19.00$85,500+5.93%
2022-08-18SaleAerovate Therapeutics, Inc.
AVTE
Chief Scientific Officer
4,500
0.0178%
$21.18$95,315-12.25%
2005-05-26SaleWindtree Therapeutics, Inc.
WINT
SVP-Preclinical Dev- Former
7,000
1.0392%
$7.08$49,560-60.73%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.